# Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BEA 2180 BR in Healthy Male Volunteers

> **NCT02254135** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BEA 2180 BR - rising dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02254135
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2007-01
- **Final completion:** —
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02254135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02254135, "Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BEA 2180 BR in Healthy Male Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02254135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*